Inhibition of melanoma tumor growth in vivo by survivin targeting
AUTOR(ES)
Grossman, Douglas
FONTE
The National Academy of Sciences
RESUMO
A role of apoptosis (programmed cell death) in tumor formation and growth was investigated by targeting the apoptosis inhibitor survivin in vivo. Expression of a phosphorylation-defective survivin mutant (Thr34→Ala) triggered apoptosis in several human melanoma cell lines and enhanced cell death induced by the chemotherapeutic drug cisplatin in vitro. Conditional expression of survivin Thr34→Ala in YUSAC2 melanoma cells prevented tumor formation upon s.c. injection into CB.17 severe combined immunodeficient-beige mice. When induced in established melanoma tumors, survivin Thr34→Ala inhibited tumor growth by 60–70% and caused increased apoptosis and reduced proliferation of melanoma cells in vivo. Manipulation of the antiapoptotic pathway maintained by survivin may be beneficial for cancer therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=14640Documentos Relacionados
- Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.
- Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
- INHIBITION OF TUMOR GROWTH BY POLYINOSINIC-POLYCYTIDYLIC ACID
- Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells
